Nine Point Two Capital LLC Revance Therapeutics, Inc. Transaction History
Nine Point Two Capital LLC
- $252 Million
- Q4 2023
A detailed history of Nine Point Two Capital LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Nine Point Two Capital LLC holds 37,496 shares of RVNC stock, worth $96,364. This represents 0.13% of its overall portfolio holdings.
Number of Shares
37,496Holding current value
$96,364% of portfolio
0.13%Shares
3 transactions
Others Institutions Holding RVNC
# of Institutions
24Shares Held
10.2MCall Options Held
360KPut Options Held
0-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL423KShares$1.09 Million0.0% of portfolio
-
Rothschild & CO Asset Management Us Inc. New York, NY370KShares$949,9950.1% of portfolio
-
International Biotechnology Trust PLC London, X0289KShares$742,0251.12% of portfolio
-
Credit Suisse Ag Zurich, V8180KShares$462,9800.0% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...